Federated Hermes Inc. Has $442,000 Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Federated Hermes Inc. reduced its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 94.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,397 shares of the medical research company's stock after selling 42,039 shares during the quarter. Federated Hermes Inc.'s holdings in Charles River Laboratories International were worth $442,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in CRL. Versant Capital Management Inc raised its stake in shares of Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock worth $30,000 after buying an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. raised its position in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after acquiring an additional 65 shares in the last quarter. Pilgrim Partners Asia Pte Ltd acquired a new stake in Charles River Laboratories International in the 4th quarter valued at about $48,000. Tortoise Investment Management LLC boosted its position in shares of Charles River Laboratories International by 77.7% during the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock valued at $49,000 after purchasing an additional 115 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new position in shares of Charles River Laboratories International in the 3rd quarter worth approximately $59,000. Institutional investors own 98.91% of the company's stock.

Analyst Upgrades and Downgrades

CRL has been the subject of a number of research reports. UBS Group restated a "neutral" rating and set a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. JPMorgan Chase & Co. decreased their target price on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a report on Thursday, February 20th. Mizuho reduced their target price on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a report on Wednesday, April 9th. Redburn Atlantic raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price target on the stock in a research note on Monday, March 3rd. Finally, Citigroup raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and upped their price objective for the company from $155.00 to $175.00 in a research note on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $182.00.

Charles River Laboratories International Stock Up 5.0 %

Shares of Charles River Laboratories International stock traded up $5.37 on Wednesday, hitting $112.26. 228,309 shares of the company traded hands, compared to its average volume of 1,491,592. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $254.15. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The company has a market cap of $5.51 billion, a PE ratio of 748.40, a PEG ratio of 4.54 and a beta of 1.45. The company has a 50-day moving average price of $149.12 and a 200 day moving average price of $172.68.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating analysts' consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. During the same quarter in the previous year, the company posted $2.46 earnings per share. The business's quarterly revenue was down 1.1% compared to the same quarter last year. Sell-side analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO James C. Foster purchased 6,075 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The stock was bought at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the transaction, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. This represents a 3.42 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the transaction, the executive vice president now directly owns 20,013 shares in the company, valued at approximately $3,252,112.50. This represents a 18.02 % decrease in their position. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by corporate insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).